Breaking News

Race Inks Agreement with Ardena for GMP Manufacturing of RC220

Partnership strengthens the existing manufacturing programs by serving as a primary source for EU compliant supplies.

Race Oncology Ltd. signed an agreement with Ardena Holding NV, global CDMO, to provide additional good manufacturing practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of bisantrene, RC220. Ardena assists biopharma companies with services spanning the drug development life cycle and provides sterile injectable products for all stages of clinical development. The partnership strengthens Race’s existing manufacturing programs by ser...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters